nach oben

Erschienen in:

01.03.2012 | Original Article

The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

verfasst von: Patrizia Chiusolo, Sabrina Giammarco, Silvia Bellesi, Elisabetta Metafuni, Nicola Piccirillo, Daniela De Ritis, Sara Marietti, Sorà Federica, Luca Laurenti, Luana Fianchi, Stefan Hohaus, Leone Giuseppe, Simona Sica

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In the last years, the influence of different genes involved in metabolism of chemotherapeutic agents has been studied. Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL) and Burkitt’s lymphomas (BL). This study aims to evaluate the role of MTHFR C677T and A1298C polymorphisms and G80A reduced folate carrier gene (RFC1) in a cohort of adult patients with lymphoproliferative malignancies submitted to high-dose MTX followed by leucovorin rescue.

Methods

We performed the analysis of these polymorphisms on genomic DNA with RFLP–PCR.

Results

Patients carrying MTHFR A1298C variant showed decreased hepatic and hematological toxicity (P = 0.03). Overall survival (OS) and progression-free survival (PFS) between homozygous wild-type and variant patients for the RFC1 G₈₀A were significantly different (P = 0.035 and P = 0.02, respectively). A significant correlation between hematological toxicity and age (P = 0.003) was observed. There was no significant influence of MTHFR C677T genotype on toxicity, OS and PFS.

Conclusions

Leucovorin rescue given after high-dose MTX probably accounts for the lack of influence of C677T polymorphism. To better define a role of RFC1 polymorphism on patients outcome, it would be worthwhile to perform a study on intracellular MTX level and RFC1 substrate binding affinities in different genotypes.

Blasco H, Senecal D, Le Gouge A et al (2010) Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. Br J Clin Pharmacol 70(3):367–375PubMedCrossRef

Yustein JT, Dang CV (2007) Biology and treatment of Burkitt’s lymphoma. Curr Opin in Hematol 14(4):375–381CrossRef

Magrath I, Adde M, Shad A, Venzon D et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14(3):925–934PubMed

Bailey LB, Gregory JF (1999) Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 129(5):919–922PubMed

Ueland PM, Hustad S, Schneede J et al (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22(4):195–201PubMedCrossRef

Chango A, Emery-Fillon N, de Courcy GP et al (2000) A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 70(4):310–315PubMedCrossRef

De Marco P, Calevo MG, Moroni A et al (2003) Reduced folate carrier polymorphism (80A→G) and neural tube defects. Eur J Hum Genet 11(3):245–252PubMedCrossRef

Shaw GM, Lammer EJ, Zhu H et al (2002) Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 108(1):1–6PubMedCrossRef

Pei L, Liu J, Zhang Y et al (2009) Association of reduced folate carrier gene polymorphism and maternal folic acid use with neural tube defects. Am J Med Genet B Neuropsychiatr Genet 150B(6):874–878PubMedCrossRef

10.

Shang Y, Zhao H, Niu B et al (2008) Correlation of polymorphism of MTHFRs and RFC-1 genes with neural tube defects in China. Birth Defects Res A Clin Mol Teratol 82(1):3–7PubMedCrossRef

11.

Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64(3):169–172PubMedCrossRef

12.

Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111–113PubMedCrossRef

13.

Trotti A, Byhardt R, Stetz J et al (2000) Common toxicity criteria: version 2.0. An improved reference for grading the acute effect of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47(1):13–47PubMedCrossRef

14.

Chiusolo P, Reddiconto G, Cimino G et al (2004) Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Haematologica 89(2):139–144PubMed

15.

Aplenc R, Thompson J, Han P et al (2005) Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 65(6):2482–2487PubMedCrossRef

16.

Krajinovic M, Lemieux-Blanchard E et al (2004) Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 4(1):66–72PubMedCrossRef

17.

Krajinovic M, Lamothe S, Labuda D et al (2004) Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 103(1):252–257PubMedCrossRef

18.

Kim HN, Kim YK, Lee IK et al (2009) Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk Res 33(1):82–87PubMedCrossRef

19.

20.

Ongaro A, De Mattei M, Della Porta MG et al (2009) Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 94(10):1391–1398PubMedCrossRef

21.

Liu JX, Chen JP, Tan W et al (2008) Association between MTHFR gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(3):488–492PubMed

22.

Kantar M, Kosova B, Cetingul N et al (2009) Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 50(6):912–917PubMedCrossRef

23.

Toffoli G, Russo A, Innocenti F et al (2003) Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103(3):294–299PubMedCrossRef

24.

Urano W, Taniguchi A, Yamanaka H et al (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12(3):183–190PubMedCrossRef

25.

Shimasaki N, Mori T, Samejima H et al (2006) Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 28(2):64–68PubMedCrossRef

26.

Seidemann K, Book M, Zimmermann M et al (2006) MTHFR 677 (C→T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol 85(5):291–300PubMedCrossRef

27.

Chiusolo P, Reddiconto G, Farina G et al (2007) MTHFR polymorphisms’ influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 31(12):1669–1674PubMedCrossRef

28.

Huang L, Tissing WJ, de Jonge R et al (2008) Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 22(9):1798–1800PubMedCrossRef

29.

de Jonge R, Hooijberg JH, van Zelst BD et al (2005) Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 106(2):717–720PubMedCrossRef

30.

Jansen G, Mauritz R, Drori S et al (1998) A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273(46):30189–30198PubMedCrossRef

31.

Whetstine JR, Gifford AJ, Witt T et al (2001) Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 7(11):3416–3422PubMed

32.

Dervieux T, Furst D, Lein DO et al (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50(9):2766–2774PubMedCrossRef

33.

Rocha JC, Cheng C, Liu W et al (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105(12):4752–4758PubMedCrossRef

34.

Lavardière C, Chiasson S, Costea I et al (2002) Polymorphism G₈₀A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and out come of childhood acute lymphoblastic leukemia. Blood 100(10):3832–3834CrossRef

35.

Ashton LJ, Gifford AJ, Kwan E et al (2009) Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia. Leukemia 23(7):1348–1351PubMedCrossRef

Titel: The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue
verfasst von: Patrizia Chiusolo
Sabrina Giammarco
Silvia Bellesi
Elisabetta Metafuni
Nicola Piccirillo
Daniela De Ritis
Sara Marietti
Sorà Federica
Luca Laurenti
Luana Fianchi
Stefan Hohaus
Leone Giuseppe
Simona Sica
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1751-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)

Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy

Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice

Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma

A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer

Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie